Latest News

BofA Securities Asia Forum Gathers Global Investors Amid Surge in Hedge Funds Allocations

Key points * BofA Securities hosted its fourth annual Asia Alternatives Forum, bringing together more than 20 hedge fund managers and 120 institutional allocators. * Allocators of approximately $700 billion in hedge fund capital discussed market conditions and investment strategies. * A Bof...

2026-06-01 09:00 7515

UOB and FPT sign MoU to advance AI, technology transformation and financial innovation opportunities

SINGAPORE, June 1, 2026 /PRNewswire/ -- UOB and global technology corporation FPT have signed a Memorandum of Understanding (MoU) to explore strategic collaboration opportunities in artificial intelligence (AI), digital and technology transformation, and financial services innovation.

2026-06-01 09:00 7272

Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting

SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis results of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product ca...

2026-06-01 08:15 6329

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved anobjective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benef...

2026-06-01 08:15 7402

MICROIP to Debut "AI Vehicle System Business Group" and Edge AI Innovations at COMPUTEX 2026

TAIPEI, June 1, 2026 /PRNewswire/ -- MICROIP (TPEx: 7796), specializing in AI software and ASIC design services, will unveil its "AI Vehicle System Business Group" at COMPUTEX 2026 (Booth A1215a, TWTC Hall 1, June 2-5). Echoing the "AI Together" theme, the showcase focuses on edge AI, smart mobil...

2026-06-01 08:00 6143

D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC

Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4 months in first-line KRAS G12C–mutant NSCLC (n=41) across all PD-L1 expression levels Combination of elisrasib with pembrolizumab achieves an ORR of 81.3% in first-line KRAS G12C–mutant NSCLC (n=48) across all PD-L1 expression ...

2026-06-01 08:00 4681

Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview

TAIPEI, June 1, 2026 /PRNewswire/ -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today highlighted a strategic vision detailed by its found...

2026-06-01 08:00 5509

ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO

SUZHOU, China, May 31, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. As of the data cut-off o...

2026-06-01 08:00 5099

2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC

* IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression. The 3→1.5 mg/kg dose group (n=22) showed ORR of 86.4%, confirmed ORR (cORR) of 81.8% (95% CI: 59.7-94.8) and DCR ...

2026-06-01 08:00 6049

2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

* After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC * IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant squamous NSCLC; pending regulatory communication...

2026-06-01 08:00 5576

New Taipei City Showcases Smart Manufacturing Strength at AUTOMATE 2026

Exploring New Business Opportunities with Global Buyers TAIPEI, May 31, 2026 /PRNewswire/ -- The New Taipei City Government is leading a delegation of 20 companies specializing in smart manufacturing, automation, industrial AI, and key components to participate in AUTOMATE 2026, one of North Ame...

2026-06-01 08:00 4827

AMD Bundles Carbice Ice Pad with Ryzen™ 7 5800X3D

* The Carbice Ice Pad provides a reliable, peel-and-stick, maintenance-free thermal paste alternative designed for consistent gaming performance over the life of a system * Partnership marks the first time consumers can experience advanced carbon nanotube CPU cooling through a mainstream reta...

2026-06-01 08:00 2643

Carbice and Noctua Partner to Bring Advanced Thermal Pad Technology to DIY PC Builders

Noctua is the exclusive retail distributor of Carbice® IP90 thermal pads for the DIY PC market, beginning with the NT-CP1 AM5/4 for AMD Ryzen™ processors ATLANTA, June 1, 2026 /PRNewswire/ -- Carbice

2026-06-01 08:00 2945

Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema

HANGZHOU, China, SHANGHAI and BOSTON, June 1, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that its internally developed Class 1 innovative drug candi...

2026-06-01 08:00 5805

United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026

LOS ANGELES, May 31, 2026 /PRNewswire/ -- United Imaging, a global innovator in AI-powered advanced medical imaging technologies and intelligent healthcare solutions, is presenting its latest molecular imaging advancements at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annu...

2026-05-31 23:00 4121

BLUETTI Launches EOFY Sale on Power Solutions with Up to 44% OFF

SYDNEY, June 1, 2026 /PRNewswire/ -- Clean energy leader BLUETTI is unleashing massive EOFY deals during June 1–30, up to 44% off its diverse portable power stations and home backup systems.The world's s...

2026-05-31 22:00 7130

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

CHICAGO, May 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-l...

2026-05-31 21:00 5001

Relief as Firmable locates 15,000 accounting decision-makers reported missing at leading global B2B data provider

Sydney-based sales team initiates platform support ticket after discovering significantly more contacts than expected. Investigation concludes that data is correct. MELBOURNE, Australia and SINGAPORE, May 31, 2026 /PRNewswire/ -- Firmable, Asia-Pacific's leading AI-native sales platform, has con...

2026-05-31 20:57 4479

AI: Digital to Physical | BEYOND Expo 2026 Leads Transformative Global Direction of Tech

MACAO, May 31, 2026 /PRNewswire/ -- The BEYOND Expo 2026 has shown what the future looks like as it delivers on its mission of 'Empowering Asia, Bridging the World' with a heavyweight showcase of the latest emerging technology and ideas from Asia. Held at The Venetian Cotai Expo with the theme "A...

2026-05-31 14:32 4324

Golden Goblet Competition Lineup Announced: Spotlight on the 2026 Contenders

SHANGHAI, May 30, 2026 /PRNewswire/ -- The 28th Shanghai International Film Festival (SIFF) has officially unveiled the competition selections for the 2026 Golden Goblet Awards.   Held from June 12 to 21, the Festival received approximately 4,100 submissions from 125 countries and regions this ...

2026-05-31 10:33 9396